Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04937153 | GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies | completed | Phase 1 | 18 | GenmabINDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06443710 | Technetium [99mTc]-H7ND in Patients With Gastrointestinal Malignancies and Healthy Volunteers | completed | Phase 1 | 24 | Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.OTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT01286896 | Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors | completed | Phase 1 | 43 | The Netherlands Cancer InstituteOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT05323045 | A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 | completed | Phase 1 | 31 | Byondis B.V.INDUSTRY | 4 | Jul 9, 2025 | clinicaltrials |
| NCT01628640 | Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors | completed | Phase 1 | 17 | Mayo ClinicOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03520075 | Study of ASTX029 in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 192 | Taiho Oncology, Inc.INDUSTRY | 4 | Jul 3, 2025 | clinicaltrials |
| NCT05487235 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 57 | Genentech, Inc.INDUSTRY | 6 | Jul 3, 2025 | clinicaltrials |
| NCT00540982 | Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction | completed | Phase 1 / Phase 2 | 47 | City of Hope Medical CenterOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03884556 | TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | completed | Phase 1 | 56 | Trishula Therapeutics, Inc.INDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT05383703 | Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor(MNC-168) | completed | Phase 1 | 12 | Moon (Guangzhou) Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03990233 | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | completed | Phase 1 | 100 | OSE ImmunotherapeuticsINDUSTRY | 2 | Jun 26, 2025 | clinicaltrials |
| NCT02279433 | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b | completed | Phase 1 | 46 | Nuvation Bio Inc.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT04730843 | A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors | completed | Phase 1 | 18 | Elpiscience Biopharma, Ltd.INDUSTRY | 1 | Jun 23, 2025 | clinicaltrials |
| NCT04991506 | A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Elpiscience Biopharma, Ltd.INDUSTRY | 1 | Jun 23, 2025 | clinicaltrials |
| NCT06007482 | A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 12 | Elpiscience Biopharma Australia Pty. Ltd.INDUSTRY | 1 | Jun 23, 2025 | clinicaltrials |
| NCT04975958 | Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors | completed | Phase 1 | 47 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07030439 | A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State | completed | Phase 1 | 32 | Impact Therapeutics, Inc.INDUSTRY | 1 | Jun 22, 2025 | clinicaltrials |
| NCT04278859 | Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies | completed | Phase 1 | 47 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT05625412 | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | completed | Phase 1 | 70 | Bristol-Myers SquibbINDUSTRY | 9 | Jun 13, 2025 | clinicaltrials |
| NCT06381050 | The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors | completed | Phase 1 | 76 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 13, 2025 | clinicaltrials |
| NCT07019194 | An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition | completed | Phase 1 | 40 | Impact Therapeutics, Inc.INDUSTRY | 1 | Jun 13, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT02517918 | Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma(METZOLIMOS) | completed | Phase 1 | 23 | Institut BergoniéOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04393298 | A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 93 | UCB Biopharma SRLINDUSTRY | 2 | May 29, 2025 | clinicaltrials |
| NCT00529438 | RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies | completed | Phase 1 | 47 | BiogenINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT06208124 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Immuneering CorporationINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT04972981 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | completed | Phase 1 | 30 | ADC Therapeutics S.A.INDUSTRY | 3 | May 22, 2025 | clinicaltrials |
| NCT02799095 | A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors | completed | Phase 1 / Phase 2 | 243 | Mural Oncology, IncINDUSTRY | 7 | May 21, 2025 | clinicaltrials |
| NCT04555837 | Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | completed | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT05759949 | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | completed | Phase 1 | 41 | Relay Therapeutics, Inc.INDUSTRY | 1 | May 16, 2025 | clinicaltrials |
| NCT04914286 | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 148 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 2 | May 14, 2025 | clinicaltrials |
| NCT05075564 | A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 8 | Elpiscience Biopharma, Ltd.INDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT04383938 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 40 | Aprea TherapeuticsINDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT04328740 | Phase 1 Study of Oral TP-1454 | completed | Phase 1 | 31 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT05377528 | Study of AGEN1571 in Participants With Advanced Solid Tumors | completed | Phase 1 | 22 | Agenus Inc.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05306444 | CLN-418 Study on Subjects With Advanced Solid Tumors | completed | Phase 1 | 48 | Harbour BioMed US, Inc.INDUSTRY | 2 | Apr 25, 2025 | clinicaltrials |
| NCT03260322 | A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | completed | Phase 1 | 169 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Apr 24, 2025 | clinicaltrials |
| NCT03544905 | Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33 | completed | Phase 1 | 206 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT03954067 | A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors | completed | Phase 1 | 72 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04836195 | Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | completed | Phase 1 | 29 | Pacylex PharmaceuticalsINDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT04886622 | A Study of DT2216 in Relapsed/Refractory Malignancies | completed | Phase 1 | 20 | Dialectic Therapeutics, IncINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT00576654 | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 73 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2025 | clinicaltrials |
| NCT04774952 | Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors | completed | Phase 1 | 58 | Revolution Medicines, Inc.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT04720976 | JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 58 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 11, 2025 | clinicaltrials |
| NCT03724890 | Study of Avelumab-M3814 Combinations | completed | Phase 1 | 57 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04943900 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | completed | Phase 1 | 67 | Bristol-Myers SquibbINDUSTRY | 7 | Apr 9, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 16, 2025source: clinicaltrials